Docosahexaenoic acid in Multiple Sclerosis: ACTRN12626000924358 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Not Applicable
Clinical phase
Not yet recruiting
Recruitment status
13
Planned enrollment
Timing not reported
Primary-completion proxy
Executive view
ACTRN12626000924358 evaluates Docosahexaenoic acid in Multiple Sclerosis. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is Australia. The first listed primary endpoint is not reported, assessed over an unreported time frame.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for ACTRN12626000924358 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Multiple Sclerosis landscape. Drug & Asset MCP drug_fetch was queried for Docosahexaenoic acid, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| ACTRN12626000924358 | Docosahexaenoic acid | Not Applicable / Not yet recruiting | Sponsor not reported | Australia | Timing not reported | |
| NCT07756268 | SYS-6020 | Phase 1/2 / Not yet recruiting | Huazhong University of Science Tongji Hospital, Tongji Medical College | China | Safety and tolerability From informed consent through Month 24 | 2029-02-07 |
| NCT07748637 | GT802 (Vivacta Biotechnology (Shanghai) Co., Ltd.) | Early Phase 1 / Not yet recruiting | Sponsor not reported | China | Proportion of participants experiencing dose limiting toxicity 28 days | 2031-07-30 |
| NCT07749157 | RO7845860 (F. Hoffmann-La Roche Ltd.) | Phase 1 / Not yet recruiting | Hoffmann-La Roche, Inc. | Geography not reported | Part 1, 2 and 3: Incidence and Severity of Adverse Events (AEs) From Baseline up to approximately Week 96 | 2031-02-28 |
| NCT07667322 | Ocrelizumab | Phase 1 / Recruiting | Hoffmann-La Roche Ltd. | United States, Brazil, United Kingdom, Mexico | Number of Participants With Adverse Events (AEs) Up to 168 weeks | 2028-02-15 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
ACTRN12626000924358 is a Not Applicable, not yet recruiting study with 13 planned participants. Allocation is Non-randomised trial, masking is Open (masking not used), and the intervention model is not reported.
The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: Proportion of people achieving Omega-3 index (O3I) greater than or equal to 8% at 12 and 16 weeks of supplementation.[Omega-3 analysis - Self collected finger prick dried blood spot (DBS) samples Week 0 (baseline), Week 12 and Week 16 post-commencement of intervention (end of study)].
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 13 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
4 recent result records were selected as contextual evidence for Multiple Sclerosis. These records do not establish direct evidence for ACTRN12626000924358 unless the registration number matches.
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients…
Phase 3; n=236; Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration(Mean): Geometric Mean Ratio = 1.2851(90% CI, 1.2258 - 1.3473); Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration(Mean) = 3500 micrograms/milliliters*day (µg/mL*day) (Standard Deviation, 914) Source: https://clinicaltrials.gov/ct2/show/results/NCT05232825
Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Phase 2; n=75; Percentage of Participants With Protective Antibody Titers After Vaccination = 93.5 percentage of pts ; Percentage of Participants With Protective Antibody Titers After Vaccination = 93.5 percentage of pts Source: https://clinicaltrials.gov/ct2/show/results/NCT00505063
A Phase IIIB Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary P…
Phase 3; n=769; Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)(Median) = 158.7 weeks (95% Confidence Interval, 120.0 - NA); Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)(Median) = 169.0 weeks (95% Confidence Interval, 144.1 - NA) Source: https://clinicaltrials.gov/ct2/show/results/NCT04548999
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Docosahexaenoic acid is indexed as Small molecule drug with AHSG x TRPC3 x TRPC6 biology and a global stage of Preclinical. The asset profile lists DSM Biomedical, Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Docosahexaenoic acid is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: ACTRN12626000924358
Protocol source: https://anzctr.org.au/ACTRN12626000924358.aspx
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Docosahexaenoic acid in Multiple Sclerosis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and Timing not reported the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
